Format

Send to

Choose Destination
See comment in PubMed Commons below
Schizophr Bull. 2008 Jul;34(4):664-9. doi: 10.1093/schbul/sbn035. Epub 2008 May 9.

Implications of clinical trial design on sample size requirements.

Author information

1
Weill Medical College of Cornell University, New York, NY 10065, USA. acleon@med.cornell.edu

Abstract

The primary goal in designing a randomized controlled clinical trial (RCT) is to minimize bias in the estimate of treatment effect. Randomized group assignment, double-blinded assessments, and control or comparison groups reduce the risk of bias. The design must also provide sufficient statistical power to detect a clinically meaningful treatment effect and maintain a nominal level of type I error. An attempt to integrate neurocognitive science into an RCT poses additional challenges. Two particularly relevant aspects of such a design often receive insufficient attention in an RCT. Multiple outcomes inflate type I error, and an unreliable assessment process introduces bias and reduces statistical power. Here we describe how both unreliability and multiple outcomes can increase the study costs and duration and reduce the feasibility of the study. The objective of this article is to consider strategies that overcome the problems of unreliability and multiplicity.

PMID:
18469326
PMCID:
PMC2632464
DOI:
10.1093/schbul/sbn035
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center